Rebeca Rodríguez-Veiga

Instituto de Investigación Sanitaria La Fe

Spain

Research Interests

Explore related searches

Professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (15)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (12)

ISABEL CANO FERRI

Instituto de Investigación Sanitaria La Fe

SPAIN

View details

Eduardo Anguita Mandly

Professor (Profesor Titular)

Universidad Complutense de Madrid

SPAIN

View details

ROSA MARIA AYALA DIAZ

Full Professor

Universidad Complutense de Madrid

SPAIN

View details

Javier Marco-Ayala

Universidad de Murcia

SPAIN

View details

María-Belén Vidriales

Universidad de Salamanca

SPAIN

View details

Irum Khan

University of Illinois System

UNITED STATES

View details

Juan Manuel Alonso-Dominguez

Universidad Autónoma de Madrid

SPAIN

View details

Alicia Roldán Pérez

Universidad Europea de Madrid SLU

SPAIN

View details

Miguel Sanz

Full Professor - Honorary Professor

University of Valencia

SPAIN

View details

José Vicente Gil

Instituto de Investigación Sanitaria La Fe

SPAIN

View details

MJ Calasanz

Full Professor of Genetics

Universidad de Navarra

SPAIN

View details

Ramón García-Sanz

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Rebeca Rodríguez-Veiga

Research Interests

Explore related searches

Contact this professor

Articles (15)

Feasible and Rapid Screening of IDH1/2 and FLT3-TKD2 Mutations by High-Resolution Melting for Patients with Acute Myeloid Leukemia

Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry

Healthcare Resource Utilization and Treatment Costs for Blastic Plasmacytoid Dendritic Cell Neoplasm: A PETHEMA Study

Cardiotoxicity in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia

A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold?

Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group

Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory <i>FLT3</i>-ITD Mutation-Positive Acute Myeloid Leukemia

Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry

Healthcare Resource Utilization among Patients between 60–75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study

No Evidence that <i>CD33</i> rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.

Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial.

Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens.

Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients.

Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-vs-host disease: Pharmacoeconomic assessment of hospital resource use in Spain.

Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study.

Collaborators (12)

ISABEL CANO FERRI

Eduardo Anguita Mandly

ROSA MARIA AYALA DIAZ

Javier Marco-Ayala

María-Belén Vidriales

Irum Khan

Juan Manuel Alonso-Dominguez

Alicia Roldán Pérez

Miguel Sanz

José Vicente Gil

MJ Calasanz

Ramón García-Sanz

Make your next move.

Rebeca Rodríguez-Veiga

Research Interests

Explore related searches

Contact this professor

Articles (15)

Feasible and Rapid Screening of IDH1/2 and FLT3-TKD2 Mutations by High-Resolution Melting for Patients with Acute Myeloid Leukemia

Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry

Healthcare Resource Utilization and Treatment Costs for Blastic Plasmacytoid Dendritic Cell Neoplasm: A PETHEMA Study

Cardiotoxicity in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia

A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold?

Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group

Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory <i>FLT3</i>-ITD Mutation-Positive Acute Myeloid Leukemia

Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry

Healthcare Resource Utilization among Patients between 60&ndash;75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study

No Evidence that <i>CD33</i> rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.

Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial.

Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens.

Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients.

Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-vs-host disease: Pharmacoeconomic assessment of hospital resource use in Spain.

Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study.

Collaborators (12)

ISABEL CANO FERRI

Eduardo Anguita Mandly

ROSA MARIA AYALA DIAZ

Javier Marco-Ayala

María-Belén Vidriales

Irum Khan

Juan Manuel Alonso-Dominguez

Alicia Roldán Pérez

Miguel Sanz

José Vicente Gil

MJ Calasanz

Ramón García-Sanz

Make your next move.

Healthcare Resource Utilization among Patients between 60–75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study